Trials / Completed
CompletedNCT06318676
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide (BMS-986348, CC-92480) in Adult Participants With Normal Renal Function, Severe Renal Impairment, and End-stage Renal Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 82 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mezigdomide | Specified dose on specified days |
Timeline
- Start date
- 2024-03-21
- Primary completion
- 2024-11-15
- Completion
- 2024-11-15
- First posted
- 2024-03-19
- Last updated
- 2025-06-04
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06318676. Inclusion in this directory is not an endorsement.